Phaseline

Companies › Kira Pharmacenticals (US)

Kira Pharmacenticals (US): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KP104
Feline Leukemia Virus subclass C receptor (FLVCR2) antagonist
–Phase 2GlomerulonephritisDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05517980KP104Phase 2GlomerulonephritisGenitourinaryDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Veloxis Pharmaceuticals Juro Sciences Vifor Fresenius Medical Care Renal Pharma Vaneltix Pharma Tioga Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.